Mounjaro approved to reduce cardiovascular risk in type 2 diabetes

Eli Lilly said on August 28, 2026 that the FDA approved Mounjaro (tirzepatide) to lower the risk of major adverse cardiovascular events — cardiovascular death, non-fatal heart attack or non-fatal stroke — in adults with type 2 diabetes who are at high risk for those events ^[1][4]. Mounjaro was already approved as an add-on to diet and exercise to improve blood sugar in adults and children 10 and older with type 2 diabetes ^[1].

The new wording now appears in the drug's prescribing information, which was updated in August 2026 to add the cardiovascular indication ^[2]. Lilly describes Mounjaro, a dual GIP and GLP-1 receptor agonist, as the first and only medicine in that class with an FDA-cleared cardiovascular risk-reduction claim ^[1][5].

What the trial showed

The approval rests on SURPASS-CVOT, which Lilly calls the first cardiovascular outcomes trial to compare two incretin medicines head-to-head instead of against placebo ^[1][4]. The trial randomized 13,299 adults with type 2 diabetes and established atherosclerotic cardiovascular disease 1:1 across 640 sites in 30 countries. One group received Mounjaro at 15 mg or the maximum tolerated dose; the other received Trulicity (dulaglutide) 1.5 mg, both once weekly by injection ^[4].

Over a median follow-up of 210.1 weeks — roughly four years — Mounjaro met the trial's main goal of non-inferiority to dulaglutide for three-point MACE. The hazard ratio for time to first event was 0.92 (95.3% confidence interval 0.83 to 1.01), which Lilly describes as an 8% lower rate of cardiovascular death, heart attack or stroke ^[1][4]. Events occurred in an estimated 12% of patients on tirzepatide versus 13% on dulaglutide ^[5].

That difference was not statistically significant. Lilly states plainly that "superiority to dulaglutide was not established" ^[4]. In other words, the trial showed tirzepatide protected the heart about as well as a GLP-1 drug that already carries a cardiovascular claim, not that it protected better. Trulicity is approved in adults with type 2 diabetes to reduce the risk of major cardiovascular events in people with established cardiovascular disease or multiple risk factors ^[1]. Full results were published in The New England Journal of Medicine ^[4].

Safety in the trial was generally consistent with tirzepatide's known profile. The most common adverse events were gastrointestinal, mostly mild to moderate, and occurred mainly during dose escalation ^[1][5]. Separately, the August 2026 label update also revised the warning on diabetic retinopathy complications, advising that patients with a history of diabetic retinopathy be monitored for progression ^[2].

Why it matters for patients

For people with type 2 diabetes and heart risk, the practical change is what the label now says a drug is proven to do. Lilly notes that heart disease is the leading cause of death in type 2 diabetes and estimates as many as one in three US adults with the condition have undetected cardiovascular disease ^[1][4]. An on-label cardiovascular indication can matter for insurance coverage and prior authorization decisions, because payers often tie approval criteria to labeled uses.

It also changes the comparison shoppers and prescribers make. Because the benchmark was an active drug rather than placebo, the results say Mounjaro is a reasonable alternative to dulaglutide on cardiovascular outcomes — not that switching would deliver extra heart protection. The 8% figure comes with a confidence interval that crosses 1.00 ^[1][4].

The dosing framework did not change: the labeled starting dose is 2.5 mg once weekly, with a maximum of 15 mg weekly in adults and 10 mg weekly in patients 10 and older ^[2]. Mounjaro carries a boxed warning about thyroid C-cell tumors seen in rats and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with MEN 2 ^[2]. Other labeled risks include pancreatitis, hypoglycemia when combined with insulin or sulfonylureas, kidney injury from dehydration, gallbladder disease, severe GI reactions and aspiration during anesthesia ^[1][2].

The sources do not address whether this cardiovascular indication extends to Zepbound, the same molecule marketed for weight management, so that remains unclear.

What happens next

The label revision is dated August 2026, and the DailyMed record shows the prescribing information was updated August 27, 2026 ^[2]. Trial data are already reflected in Mounjaro's product information in the European Union, and Lilly says regulatory submissions based on SURPASS-CVOT are under review in additional markets, though it did not name them or give decision dates ^[4]. Pricing and coverage changes tied to the new indication were not announced ^[1][4].